- Home
- IREN vs AAPG Comparison
IREN vs AAPG Comparison
Compare IREN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IREN
- AAPG
- Stock Information
- Founded
- IREN 2018
- AAPG 2009
- Country
- IREN Australia
- AAPG China
- Employees
- IREN N/A
- AAPG N/A
- Industry
- IREN EDP Services
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- IREN Technology
- AAPG Health Care
- Exchange
- IREN Nasdaq
- AAPG Nasdaq
- Market Cap
- IREN 4.4B
- AAPG 3.6B
- IPO Year
- IREN 2021
- AAPG 2025
- Fundamental
- Price
- IREN $19.35
- AAPG $44.43
- Analyst Decision
- IREN Strong Buy
- AAPG Buy
- Analyst Count
- IREN 10
- AAPG 1
- Target Price
- IREN $19.67
- AAPG N/A
- AVG Volume (30 Days)
- IREN 25.4M
- AAPG 7.0K
- Earning Date
- IREN 08-28-2025
- AAPG 08-20-2025
- Dividend Yield
- IREN N/A
- AAPG N/A
- EPS Growth
- IREN N/A
- AAPG N/A
- EPS
- IREN N/A
- AAPG N/A
- Revenue
- IREN $377,821,000.00
- AAPG $134,352,180.00
- Revenue This Year
- IREN $169.71
- AAPG N/A
- Revenue Next Year
- IREN $84.23
- AAPG $404.41
- P/E Ratio
- IREN N/A
- AAPG N/A
- Revenue Growth
- IREN 128.24
- AAPG 341.77
- 52 Week Low
- IREN $5.13
- AAPG $16.50
- 52 Week High
- IREN $21.54
- AAPG $43.58
- Technical
- Relative Strength Index (RSI)
- IREN 59.26
- AAPG N/A
- Support Level
- IREN $17.56
- AAPG N/A
- Resistance Level
- IREN $19.38
- AAPG N/A
- Average True Range (ATR)
- IREN 1.16
- AAPG 0.00
- MACD
- IREN -0.04
- AAPG 0.00
- Stochastic Oscillator
- IREN 70.12
- AAPG 0.00
About IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.